YHC 1108
Alternative Names: YHC-1108Latest Information Update: 01 Jun 2021
At a glance
- Originator Yuhan
- Developer Gilead Sciences; Yuhan
- Class Anti-inflammatories; Hepatoprotectants; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-alcoholic steatohepatitis
Most Recent Events
- 31 May 2021 Preclinical trials in Non-alcoholic steatohepatitis in USA, South Korea (unspecified route) before May 2021 (Yuhan pipeline, May 2021)